RecruitingNot ApplicableNCT05561738

Nicotinamide Riboside in Ulcerative Colitis


Sponsor

University of Pittsburgh

Enrollment

40 participants

Start Date

Feb 28, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).


Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether a supplement called nicotinamide riboside (a form of vitamin B3) can help children with ulcerative colitis (UC) — a form of inflammatory bowel disease that causes chronic inflammation in the large intestine. Researchers hope it may reduce inflammation and ease symptoms in younger patients. **You may be eligible if...** - Your child is 18 years old or younger - Your child has been diagnosed with mild to moderate ulcerative colitis confirmed by colonoscopy - Both newly diagnosed children and those with established disease may enroll **You may NOT be eligible if...** - Your child has severe ulcerative colitis (a medical emergency) - Your child has an active gut infection (such as C. difficile or CMV) - Your child has Crohn's disease or indeterminate colitis - Your child has received steroids or antibiotics in the past 3 months (unless on a stable biologic for at least 3 months) - Your child has another chronic inflammatory or autoimmune disorder, or a prior cancer - Your child is pregnant - Your child has kidney or liver problems - Your child's platelet count is below 50,000 Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTNicotinamide Riboside Chloride

The intervention consists of 6 months to 1 year of daily oral therapy with Nicotinamide Riboside Chloride (Niagen) in addition to standard therapy.

DIETARY_SUPPLEMENTPlacebo

The intervention consists of 6 months to 1 year of daily oral therapy with placebo (Maltodextran capsules of similar size, shape and color as Niagen) in addition to standard therapy.

OTHERStandard of Care

Standard of Care


Locations(1)

UPMC Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05561738


Related Trials